Intellia presents positive data for hereditary angioedema treatment
Investing.com - UBS upgraded DiaSorin SpA (BIT:DIA) (OTC:DSRLF) from Neutral to Buy on Wednesday, raising its price target to EUR98.00 from EUR95.00.
The upgrade comes despite DiaSorin shares falling 20% year-to-date, reflecting investor concerns about near-term guidance feasibility and midterm growth sustainability following a challenging 2025 performance.
UBS believes these investor concerns are unjustified, noting that DiaSorin has delivered above-market average organic revenue growth of 7% over the past 18 months, which reflects a "considered strategic pivot to underpenetrated niches."
The firm’s analysis indicates that DiaSorin will meet its FY25 guidance, albeit potentially at the lower end, and forecasts accelerating growth in 2026 leading to a 7% midterm revenue compound annual growth rate.
UBS cited its "deep-dive analysis" showing that DiaSorin’s end-markets are not as saturated as investors fear, combined with a "rich catalyst path" while shares currently price in substantial downgrades.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.